As from April 2013 my Journey in Investing is to create Retirement Income for Life till 85 years old in 2041 for two persons over market cycles of Bull and Bear.

Click to email CW8888 or Email ID :

Welcome to Ministry of Wealth!

This blog is authored by an old multi-bagger blue chips stock picker uncle from HDB heartland!

"The market is not your mother. It consists of tough men and women who look for ways to take money away from you instead of pouring milk into your mouth." - Dr. Alexander Elder

"For the things we have to learn before we can do them, we learn by doing them." - Aristotle

It is here where I share with you how I did it! FREE Education in stock market wisdom.

Think Investing as Tug of War - Read more? Click and scroll down

Important Notice and Attention: If you are looking for such ideas; here is the wrong blog to visit.

Value Investing
Dividend/Income Investing
Technical Analysis and Charting
Stock Tips

Wednesday, 7 November 2012


Q2 FY13 and Recent Highlights:
Total revenue of US$79.8 million, representing 28% year-on-year growth

Interventional Cardiology Products (IVP) sales, largely comprising drug-eluting stent (DES) sales, increased substantially by 61% year-on-year to US$61.9 million

Gross margin on total product sales was 80%, a significant improvement of 9% year-on-year

Operating profit reached US$33.9 million, a 71% year-on-year increase, while net profit excluding exceptional items grew 36% year-on-year to US$29.2 million

A study published in August in the Journal of the American Medical Association (
JAMA) confirms BioMatrix™reduces cardiac events in acute myocardial infarction (AMI) patients more effectively than a bare-metal stent

In October, Biosensors extended its licensing agreement with Terumo for territories outside the United States and Japan and positions itself for more strategic cooperation with Terumo in all sales territories, including Japan

At the Transcatheter Cardiovascular Therapeutics (
TCT) conference in October, the Company released the final 5-year results for its ground-breaking LEADERS trial, demonstrating improved long-term clinical outcomes for BioMatrix Flex as compared to Cypher® Select™

See? Presentation slides

No comments:

Post a comment

Related Posts with Thumbnails